Paper Title
METFORMIN AS A NOVEL INHIBITOR FOR MITIGATING PLATELET AGGREGATION IN HUMAN SUBJECTS

Abstract
Abstract -Metformin is extensively prescribed as a first-line medication for the management of type 2 diabetes (T2D), a condition frequently coexisting with kidney disease, cardiovascular diseases (CVDs), and retinopathy. The widespread use of metformin is attributed to its well-established safety profile. Notably, platelets play a crucial role in arterial thrombosis, a significant factor contributing to the development of CVDs and cerebrovascular diseases. In this study, metformin inhibited platelet aggregation stimulated by thrombin in a concentration-dependent manner. Metformin suppressed P-selectin expression, [Ca2+]i mobilization and ATP-release in human platelets. In conclusion, metformin can potentially function as a therapeutic agent for the prevention of CVDs and other relative diseases. Keywords - Arterial Thrombosis, Human Platelets, METFORMIN, Thrombin.